Is AI Drug Discovery Actually Working? What the 2026 Clinical Trial Data Shows
Dr. Dereck Mush, MD, MBA
What they do
Atomwise developed AtomNet, a deep learning neural network that predicts how molecules will interact with target proteins. The technology helps academic institutions and pharmaceutical firms identify promising drug compounds out of millions of virtual candidate molecules.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- AI drug discovery
- Product type
- Platform software
- Stage
- Series B
- Headquarters
- San Francisco, United States
- Region
- North America
- Founded
- 2012
- Total funding
- $174M raised
Notable investors: Bessemer Venture Partners, B Capital Group, DFJ Growth, Tencent Holdings.
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
AI is moving upstream, from molecule design into disease target identification itself
Dr. Dereck Mush, MD, MBA